The Food and Drug Administration is investigating the safety of the popular asthma medication Xolair. The five year observational study of the long term effects of the drug have found that patients using the injectable drug may lead to strokes, heart attacks, irregular heartbeats, hypertension and other heart problems.
Xolair is manufactured by Genetech and marketed by Novartis and was approved in 2003 by the FDA for patients with moderate to severe asthma in which inhalable treatments do not work. There is no recall yet on the product and the FDA is telling patients to continue to use the medication. The current observational health study is set to end in 2012 but the FDA is working to conduct a new study that will be better able to evaluate the risks associated with the drug.
If you believe that you or a loved one has been harm as a result of Xolair or any other medication do not hesitate to contact our experienced pharmaceutical lawyers to discuss your potential case.
